142 related articles for article (PubMed ID: 33753712)
1. Construction of Decision Trees Based on Gene Expression Omnibus Data to Classify Bladder Cancer and Its Subtypes.
Zhou JQ; Kang XL; Xu CJ; Liu S; Wang Y
Med Sci Monit; 2021 Mar; 27():e929394. PubMed ID: 33753712
[TBL] [Abstract][Full Text] [Related]
2. High ORAI3 expression correlates with good prognosis in human muscle-invasive bladder cancer.
Yan J; Yu W; Lu C; Liu C; Wang G; Jiang L; Jiang Z; Qin Z
Gene; 2022 Jan; 808():145994. PubMed ID: 34626722
[TBL] [Abstract][Full Text] [Related]
3. Construction and verification of a prognostic risk model based on immunogenomic landscape analysis of bladder caner.
Zhang Y; Xie Y; Feng Y; Wang Y; Xu X; Zhu S; Xu F; Feng N
Gene; 2022 Jan; 808():145966. PubMed ID: 34530089
[TBL] [Abstract][Full Text] [Related]
4. Extracellular matrix-related genes play an important role in the progression of NMIBC to MIBC: a bioinformatics analysis study.
Zhang H; Shan G; Song J; Tian Y; An LY; Ban Y; Luo GH
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32391563
[TBL] [Abstract][Full Text] [Related]
5. Profiles of Immune Infiltration in Bladder Cancer and its Clinical Significance: an Integrative Genomic Analysis.
Wu Z; Zhu K; Liu Q; Liu Y; Chen L; Cui J; Guo H; Zhou N; Zhu Y; Li Y; Shi B
Int J Med Sci; 2020; 17(6):762-772. PubMed ID: 32218698
[TBL] [Abstract][Full Text] [Related]
6. Identification of a 13‑mRNA signature for predicting disease progression and prognosis in patients with bladder cancer.
Yin H; Zhang C; Gou X; He W; Gan D
Oncol Rep; 2020 Feb; 43(2):379-394. PubMed ID: 31894276
[TBL] [Abstract][Full Text] [Related]
7. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
8. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
9. Screening of differentially expressed genes related to bladder cancer and functional analysis with DNA microarray.
Huang YD; Shan W; Zeng L; Wu Y
Asian Pac J Cancer Prev; 2013; 14(8):4553-7. PubMed ID: 24083701
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of immune molecular subtypes and microenvironment characteristics of bladder cancer.
Cao J; Li J; Yang X; Li P; Yao Z; Han D; Ying L; Wang L; Tian J
Cancer Med; 2021 Aug; 10(15):5375-5391. PubMed ID: 34165261
[TBL] [Abstract][Full Text] [Related]
11. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
[TBL] [Abstract][Full Text] [Related]
12. Four novel biomarkers for bladder cancer identified by weighted gene coexpression network analysis.
Yan X; Guo ZX; Liu XP; Feng YJ; Zhao YJ; Liu TZ; Li S
J Cell Physiol; 2019 Aug; 234(10):19073-19087. PubMed ID: 30927274
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide screening of abberant methylated drivers combined with relative risk loci in bladder cancer.
Zhang C; Shen K; Zheng Y; Qi F; Luo J
Cancer Med; 2020 Jan; 9(2):768-782. PubMed ID: 31794632
[TBL] [Abstract][Full Text] [Related]
14. Systematic screening of protein-coding gene expression identified HMMR as a potential independent indicator of unfavorable survival in patients with papillary muscle-invasive bladder cancer.
Yang D; Ma Y; Zhao P; Ma J; He C
Biomed Pharmacother; 2019 Dec; 120():109433. PubMed ID: 31568988
[TBL] [Abstract][Full Text] [Related]
15. Identification of Potential Biomarkers Associated with Prognosis in Gastric Cancer via Bioinformatics Analysis.
Li D; Yin Y; He M; Wang J
Med Sci Monit; 2021 Feb; 27():e929104. PubMed ID: 33582701
[TBL] [Abstract][Full Text] [Related]
16. Bladder cancer outcome and subtype classification by gene expression.
Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
[TBL] [Abstract][Full Text] [Related]
17. Gene discovery in bladder cancer progression using cDNA microarrays.
Sanchez-Carbayo M; Socci ND; Lozano JJ; Li W; Charytonowicz E; Belbin TJ; Prystowsky MB; Ortiz AR; Childs G; Cordon-Cardo C
Am J Pathol; 2003 Aug; 163(2):505-16. PubMed ID: 12875971
[TBL] [Abstract][Full Text] [Related]
18. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
19. Identification of immune-related genes as prognostic factors in bladder cancer.
Zhu J; Wang H; Ma T; He Y; Shen M; Song W; Wang JJ; Shi JP; Wu MY; Liu C; Wang WJ; Huang YQ
Sci Rep; 2020 Nov; 10(1):19695. PubMed ID: 33184436
[TBL] [Abstract][Full Text] [Related]
20. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
Chen F; Wang Q; Zhou Y
BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
